Faron Pharmaceuticals Oy (HEL: FARON)

Market Cap	217.89M
Revenue (ttm)	n/a
Net Income (ttm)	-31.61M
Shares Out	n/a
EPS (ttm)	-0.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	403,226
Open	2.120
Previous Close	2.120
Day's Range	2.100 - 2.250
52-Week Range	1.054 - 4.480
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 4, 2024

About Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company’s lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. T...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 34
• Stock Exchange: Nasdaq Helsinki
• Ticker Symbol: FARON